Has Shashi Patel received payments from drug or device companies?

Yes. Drug and device makers reported $3,325 in general payments to Shashi Patel across 106 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shashi Patel did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shashi Patel come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shashi Patel

Pulmonary Disease · Far Rockaway, NYNPI 1306868161

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by GSK at 30.3% of the total. Reporting peaked in 2019 at $1,199 and has fallen 97.6% since, to $29 in 2025.

$3,325in general payments, 2019–2025

Across 106 payments — averaging $31.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$1K
AstraZeneca$610
Insmed, Inc.$288
Boehringer Ingelheim$237
Abbott$175
Pfizer$141
plus $867 from 17 others

What the payments were for

Food & beverage$3,320100%
Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	30	$1,007
AstraZeneca	10	$610
Insmed, Inc.	11	$288
Boehringer Ingelheim	11	$237
Abbott	1	$175
Pfizer	2	$141
Vyaire Medical, Inc.	2	$125
Circassia Inc.	5	$94
Electromed, Inc.	5	$69
Regeneron Healthcare Solutions, Inc.	3	$62
Actelion Pharmaceuticals US, Inc.	2	$61
Mylan Specialty L.p.	3	$57
Philips North America LLC	3	$52
AbbVie	2	$48
Jazz Pharmaceuticals Inc.	2	$44
Sunovion Pharmaceuticals Inc.	2	$42
Optinose US, Inc.	2	$40
Teva Pharmaceuticals USA, Inc.	2	$39
Advanced Respiratory, Inc	2	$34
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$33
Merck	2	$31
Novo Nordisk	1	$18
Pacira Pharmaceuticals Incorporated	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,325 in reported general payments places this provider in the 65th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York →

Other pulmonary disease in Far Rockaway

Jeffrey WolfGreat Neck$892K
Keith HarrisPort Jefferson Station$832K
Jack MannBayside$736K
Raji AyinlaBronx$673K
Charles PowellNew York$654K
Nashat RabadiBuffalo$613K
Craig ThurmJamaica$604K
Michael MandelLarchmont$589K
Sherif El BayadiSyracuse$571K
Ali El AtatBrooklyn$482K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →